Folia Health Raises $10.5 Million Series A to Expand Patient-Centered Real-World Data Platform
Folia Health, the Boston‑based startup pioneering “home‑reported outcomes” (HROs) for patients with chronic and rare diseases, has raised US$10.5 million in a Series A funding round. The funding round was led by S3 Ventures, with participation from longtime backer Crosslink Capital and specialist healthcare fund Create Health Ventures.
Folia Health enables individuals to track symptoms, treatments, and outcomes from home — transforming their day-to-day lived health experiences into structured, research-grade data. By giving patients control over consent and data sharing, the platform provides a transparent way for people with chronic or rare conditions to contribute insights on how treatments affect them over time.
The company says that the new funding will accelerate growth across several key initiatives. First, it will enable the expansion of Folia’s user base and support the scaling of its platform to capture longitudinal real-world evidence (RWE) from a broader population of patients. Such data is increasingly valuable to life sciences companies, especially for conditions where traditional trial data and clinical records leave gaps in understanding — such as autoimmune diseases, rare kidney disorders, hematological conditions, skin diseases, and more.
Second, the funds will support the continued development and refinement of Folia’s technology infrastructure — including analytics capabilities, data‑reporting tools, and patient-facing features — to ensure that the data collected meets regulatory-quality standards and can meaningfully support research, drug development, and personalized care.
Folia’s model stands out because it centers the patient’s real-world experiences rather than relying solely on episodic clinical data. Its longitudinal tracking has already produced actionable insights in several conditions. For example, Folia recently announced a collaboration with Novartis Pharmaceuticals to launch an app-based observational study for individuals with IgA nephropathy (IgAN), allowing participants to self-report symptoms and quality-of-life changes over time. This kind of patient-sourced evidence could prove vital for understanding long-term treatment impact and variability.
Among the conditions Folia currently supports are autoimmune disorders such as lupus, eczema, and Sjögren’s syndrome, rare kidney diseases (including complement 3 glomerulopathy, IgAN, and lupus nephritis), as well as hematological disorders like Sickle cell disease and Paroxysmal nocturnal hemoglobinuria (PNH). According to company leadership, about 40,000 people worldwide are now using the Folia platform — generating continuous, patient‑generated data that could fill critical gaps in medical research and care.
Folia has also introduced a community‑insights research initiative called “Mosaic,” which allows participants with similar conditions to see aggregated, anonymized data — helping reveal insights about disease patterns, treatment effects, and quality-of-life changes over time. Mosaic is currently active for eczema and PNH users, with plans to expand to lupus and sickle cell disease in 2026. This community‑driven research feature aims to give participants direct, meaningful feedback about how similar patients are faring under comparable conditions.
With this fresh infusion of capital, Folia Health appears well positioned to scale its platform globally and deepen its collaboration with life-sciences companies seeking robust real-world evidence. As regulatory demand for patient‑centered, real-world data grows — especially for chronic and rare diseases — Folia’s patient-first model and consent-first data approach may offer a compelling new paradigm for personalized care and drug development.
